STAMFORD, Conn. / Dec 16, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 12-16 in San Francisco, CA. Management will participate in a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT. Live and archived webcasts will be... Read More

STAMFORD, Conn. / Dec 05, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines (Nasdaq: PRAX) and Stoke Therapeutics (Nasdaq: STOK) as the founding partners to its Patient Access Program for pediatric epilepsy, which provides access to whole exome sequencing. Currently, access to a definitive... Read More

STAMFORD, Conn. / Nov 22, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference from December 3-5 in New York City, NY. Management will participate in a fireside chat on Tuesday, December 3, 2024, at 1:00 p.m. ET. Live and archived webcasts will be... Read More

New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients STAMFORD, Conn. / Nov 19, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data - powered by... Read More

Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions STAMFORD, Conn. / Nov 18, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine... Read More

Data demonstrates the strength of GeneDx’s diverse database; exome diagnostic rate is high regardless of patient’s ancestral background GeneDx industry leading dataset from 46% non-white populations STAMFORD, Conn. / Nov 07, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on the critical... Read More

Data to be presented showcasing GeneDx’s ongoing commitment to spearheading industry-leading research to drive transformational clinical utility STAMFORD, Conn. / Nov 04, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American Society of Human Genetics (ASHG) annual meeting. GeneDx data will be... Read More

Achieved profitability milestone with third quarter adjusted net income 1 of $1.2M Reported third quarter 2024 revenues 2 of $76.6M with 77% year-over-year growth of exome and genome test revenue Expanded third quarter 2024 adjusted gross margins 2 to 64% Raising guidance to deliver between $284M and $290M in FY 2024 revenue GeneDx to host conference call today at 8:30 a.m. ET STAMFORD, Conn. / Oct 29, 2024 / Business Wire /... Read More

Findings published today in JAMA (Journal of the American Medical Association) reveal limitations of current screening methods and showcase the promise of advanced genomic technology to deliver equitable health care for all children STAMFORD, Conn. / Oct 24, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that JAMA , the Journal of the... Read More

Data to be presented at the International Conference on Newborn Sequencing (ICoNS) highlighting lessons learned from the GUARDIAN and Early Check newborn sequencing studies showcasing GeneDx’s deep expertise as the leader for gNBS STAMFORD, Conn. / Oct 08, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it has provided genomic newborn... Read More

STAMFORD, Conn. / Oct 03, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the third quarter of 2024 before the market opens on Tuesday, October 29, 2024. Management will host a conference call that day to discuss third quarter 2024 financial and operating results at 8:30 a.m. Eastern Time. Conference... Read More

STAMFORD, Conn. / Sep 27, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of September 23, 2024, the compensation committee of GeneDx’s board of directors granted a total of 7,700 restricted stock units (“RSUs”) to two newly hired employees as inducements material to each employee entering into employment with GeneDx.... Read More

STAMFORD, Conn. / Aug 12, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences this fall: UBS Genomic Medicine Summit – August 13-14, 2024 Dana Point, California Future of Genetic Testing - Babies and Beyond Panel on Wednesday, August 14 at 8:00 a.m. PT Morgan Stanley... Read More

STAMFORD, Conn. / Aug 09, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of June 26, 2024, the compensation committee of GeneDx’s board of directors granted seven newly hired employees 75,100 restricted stock units (“RSUs”) as inducements material to each employee entering into employment with GeneDx. The RSUs were... Read More

Faster Turnaround Time for Rapid Whole Genome Sequencing (rWGS), Buccal Sample Types and Additional Repeat Expansions to Become Commercially Available STAMFORD, Conn. / Jul 30, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced major enhancements to its Whole Genome Sequencing (WGS) offering, aiming to accelerate diagnoses and shorten the... Read More

Reported second quarter 2024 revenue from continuing operations 1 of $68.9M with 77% year-over-year growth of exome and genome test revenue Expanded second quarter 2024 adjusted gross margins 2 from continuing operations to 62% Narrowed second quarter 2024 adjusted net loss 2 to $2.7M Raising guidance to deliver between $255M and $265M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference... Read More

STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024. Management will host a conference call that day to discuss second quarter 2024 financial and operating results at 4:30 p.m. Eastern Time. Conference... Read More

New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections Increases commercial footprint and focus on accelerating utilization of rWGS services in neonatal intensive care units (NICUs) STAMFORD, Conn., June 10, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced... Read More

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access program, developed in partnership with leading biopharma companies, which aims to increase access to exome sequencing for pediatric epilepsy patients. “Receiving a genetic diagnosis can be critical in a child’s journey toward... Read More

STAMFORD, Conn., May 22, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in two upcoming investor conferences in June: Jefferies Healthcare Conference - New York City, New York Fireside chat on Wednesday, June 5 at 9:00 a.m. ET 44th Annual Goldman Sachs Global Healthcare Conference - Miami,... Read More

Reported first quarter 2024 revenue from continuing operations 1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins 2 from continuing operations to 61% Narrowed first quarter 2024 adjusted net loss 2 to $8.5M and delivered 71% year-over-year cash burn reduction Raised guidance to deliver between $235M and $245M in FY 2024 revenue and reiterate path to... Read More

STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry. The new partnership will increase access to GeneDx's extensive de-identified rare disease data set, now available through Komodo Health’s... Read More

STAMFORD, Conn., April 04, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024. Management will host a conference call that day to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time. Conference... Read More

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. Across one platform presentation, an industry symposium and six poster presentations, including one selected as a “Rapid Fire Poster... Read More

STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA. Management will participate in a fireside chat on Wednesday, March 6, 2024, at 10:30 a.m. ET. A live and archived webcast of the presentation will... Read More

Reported fourth quarter 2023 revenue from continuing operations 1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross margins 2 from continuing operations to 56% Narrowed fourth quarter 2023 adjusted net loss 2 to $17.8M and delivered 51% year-over-year cash burn reduction Issued guidance to deliver between $220M and $230M in FY 2024 revenue and... Read More

STAMFORD, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter of 2023 after the market closes on Tuesday, February 20, 2024. Management will host a conference call that day to discuss 2023 financial and operating results and share full year 2024 guidance at... Read More

STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx , a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23, 2024, the compensation committee of GeneDx’s board of directors granted newly hired employees 106,030 restricted stock units (“RSUs”) as inducements material to each employee entering into employment with GeneDx. The RSUs were... Read More

Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations 1 of more than $57M with at least 63% year-over-year revenue growth for exome and genome test revenue Reduced fourth quarter 2023 cash burn 51% year-over-year and 21% sequentially Ending December 31, 2023 cash position of at least $131 million Reiterating the path to profitability in 2025 STAMFORD, Conn., Jan. 08, 2024... Read More

STAMFORD, Conn., Dec. 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced new data to be presented at the American Epilepsy Society (AES) annual meeting in Orlando, Florida, December 1-5, 2023, that supports the use of exome sequencing as a first-tier test for patients with epilepsy. In a new study of 22,500 individuals with... Read More

STAMFORD, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Evercore ISI HealthCONx Conference this week in Miami, FL. Katherine Stueland, President and Chief Executive Officer, will participate in a fireside chat on Thursday, November 30, 2023, at 10:50 a.m. ET.... Read More

STAMFORD, Conn., Nov. 20, 2023 (GLOBE NEWSWIRE) -- GeneDx , a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of November 17, 2023, the compensation committee of GeneDx’s board of directors granted newly hired employees 10,000 restricted stock units (“RSUs”) as inducements material to each employee entering into employment with GeneDx. The RSUs were... Read More

Reported total revenue of $53M with more than 40% year-over-year growth of exome and genome test revenue Expanded gross margins to 48% in continuing operations and delivered 52% year-over-year cash burn reduction Strengthened balance sheet with $75M debt facility from Perceptive Advisors and initiated a $40M annual cost savings plan Updated guidance to deliver $187-$192M in FY 2023 revenue and reiterate path to profitability... Read More

STAMFORD, Conn., Oct. 09, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the third quarter of 2023 after the market closes on Monday, October 30, 2023. On the same day, Katherine Stueland, President and Chief Executive Officer of GeneDx, and Kevin Feeley, Chief Financial Officer of... Read More

STAMFORD, Conn., Sept. 22, 2023 (GLOBE NEWSWIRE) -- GeneDx , a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of October 1, the compensation committee of GeneDx’s board of directors granted newly-hired employees 133,998 restricted stock units (“RSUs”) as inducements material to each employee entering into employment with GeneDx. The RSUs were granted... Read More

STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS) a leader in delivering improved health outcomes through genomic and clinical insights, today announced the expansion and evolution of its executive leadership team with the appointment of Melanie Duquette as Chief Growth Officer and Jennifer (Jen) Brendel as Chief of Corporate Affairs. Both executives will report to Katherine Stueland, CEO and... Read More

STAMFORD, Conn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- GeneDx , a leader in delivering improved health outcomes through genomic and clinical insights, today announced a monumental accomplishment in its ongoing commitment to deliver personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company has successfully sequenced more than 500,000 clinical exomes, solidifying its... Read More

STAMFORD, Conn., Aug. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx , a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Genetics in Medicine , the official journal of the American College of Medical Genetics and Genomics (ACMG) has published a peer-reviewed research analysis resulting from a multi-lab collaboration involving GeneDx. The study, “ The landscape of reported VUS in... Read More

STAMFORD, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- GeneDx , a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of August 8, 2023, the compensation committee of GeneDx’s board of directors granted newly-hired employees 23,769 restricted stock units (“RSUs”) as inducements material to each employee entering into employment with GeneDx. The RSUs were granted... Read More

Accelerated whole exome and genome test volume growth by 56% year-over-year Total revenue of $48M in Q2 is inclusive of 36% year-over-year growth of exome and genome test revenue Expanded gross margins and operating expense rationalization resulting in continued cash burn reduction of 36% year-over-year Broadened network of strategic partners, including breakthrough research collaboration with PacBio and University of... Read More

NEW YORK and STAMFORD, Conn., July 19, 2023 (GLOBE NEWSWIRE) -- GeneDx , a leader in delivering improved health outcomes through genomic and clinical insights, and Prognos Health, the largest real-world integrated data marketplace, today announced a strategic partnership to shorten the treatment odyssey for rare disease patients via real world data. The partnership offers life science companies a comprehensive de-identified... Read More

STAMFORD, Conn., July 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the second quarter of 2023 after the market closes on Tuesday, August 8, 2023. On the same day, the management team from GeneDx will host a conference call to discuss financial and operating results at 4:30 p.m.... Read More

STAMFORD, Conn., June 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new data on urine mitochondrial DNA testing at the 2023 United Mitochondrial Disease Foundation’s (UMDF) Mitochondrial Medicine Symposium in Charlotte, North Carolina, June 28 - July 1, 2023. Poster: Is the m.3243A>G variant detected in... Read More

New paper published today in Nature Methods describes the PanGenome Research-Tool Kit for analyzing complex regions of the human pangenome Recently released human pangenome better represents landscape of diverse human populations STAMFORD, Conn., June 26, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today published a paper in Nature... Read More

STAMFORD, Conn., June 20, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, applauds the decisions by the states of Florida and Arizona to provide rWGS for children in the neonatal and pediatric intensive care units (NICU and PICU, respectively) who meet clinical criteria. Both states have funded the rWGS benefit in their 2023/2024 budget... Read More

STAMFORD, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that management will participate at the following investor conferences in June: Jefferies Healthcare Conference Presentation on Wednesday, June 7, 2023, at 4:00 p.m. ET 44 th Annual Goldman Sachs Global Healthcare Conference Fireside chat on Monday,... Read More

STAMFORD, Conn., May 23, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it will participate in multiple presentations at the World Orphan Drug Congress in Washington, D.C., May 23-25, 2023. The keynote session will highlight how GeneDx’s deeply curated, 20 plus year genomic dataset combined with strong research and... Read More

STAMFORD, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it had received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company’s Class A common stock had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company had... Read More

Generated $40.7 million in first quarter 2023 pro forma revenue from continuing operations, representing a 7% increase year over year Revenue included $22.4 million in whole exome testing, representing a 22% increase year over year Ongoing cost mitigation in first quarter delivered 31% cash burn improvement year-over-year Company reaffirms pro forma full year 2023 guidance GeneDx to host conference call today at 4:30 p.m. ET... Read More

STAMFORD, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced the availability of its GenomeXpress® and GenomeSeqDx® whole genome sequencing tests with buccal swabs as an alternative sample collection option for biological parents or other immediate family members. Sequencing biological parent genomes alongside... Read More

STAMFORD, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a clarification regarding the CUSIP number for the Company’s public warrants. As previously disclosed on April 28, 2023, the Company will effect a 1-for-33 reverse split of Class A common stock, which will open for trading on the Nasdaq Global Select... Read More

STAMFORD, Conn., April 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that its board of directors has approved a 1-for-33 reverse stock split of the Company’s Class A common stock. The Class A common stock will open for trading on the Nasdaq Global Select Market on Thursday, May 4, 2023 on a split-adjusted basis under... Read More

STAMFORD, Conn., April 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023. On the same day, Katherine Stueland, President and Chief Executive Officer and Kevin Feeley, Chief Financial Officer will host a... Read More

STAMFORD, Conn., April 03, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Devin K. Schaffer has been appointed General Counsel, effective April 24, 2023. As a member of the executive leadership team, Devin will report directly to Katherine Stueland, President and CEO, and will be responsible for all legal, compliance,... Read More

Genome Sequencing and Interpretation Services Progressing Quickly for 1,000 Newborns Enrolled in Study to Date; On Track to Support up to 100,000 Study Participants in Next Four Years Initial Data and Analysis Presented at the ACMG (American College of Medical Genetics and Genomics) Annual Meeting Show Whole Genome Sequencing Identified Rare Genetic Conditions Not Otherwise Part of Standard Newborn Screening STAMFORD, Conn.,... Read More

STAMFORD, Conn., March 16, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, announced new research today at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting which demonstrates exome sequencing’s diagnostic advantages in shortening patients’ and families’ diagnostic odysseys... Read More

Financial results are in line with previously announced preliminary 2022 results; Reiterating 2023 guidance, including total revenue of $205-220 million Completed financing in January 2023 with $150 million in expected proceeds; fully funded to expected profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) (“GeneDx”... Read More

STAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate at the Cowen 43 rd Annual Healthcare Conference in Boston, MA. Katherine Stueland, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, March 7, 2023, at 2:50 p.m. ET. A live... Read More

STAMFORD, Conn., Feb. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced its contributions to eight posters, one platform presentation and one symposium session to be released at the upcoming 2023 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. The announcement coincides with Rare... Read More

STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter and full year of 2022 after the market closes on Tuesday, March 14, 2023. On the same day, Katherine Stueland, Chief Executive Officer of GeneDx, and Kevin Feeley, Chief Financial Officer of... Read More

STAMFORD, Conn., Feb. 16, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, continues to demonstrate how the study of rare disease can improve understanding of the biology of common disorders. Research published in the October 2022 issue of Nature Genetics, to which GeneDx contributed data and authorship, yields... Read More

STAMFORD, Conn., Jan. 31, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the closing of its previously announced underwritten public offering of shares of its Class A common stock (the “Underwritten Offering”) and concurrent registered direct offering of shares of its Class A common stock (the “Direct Offering” and, together with the Underwritten Offering, the “Offerings”). The total gross... Read More

Company submitted nearly one quarter of all candidate gene submissions to GeneMatcher in 2022 and collaborated on 63 publications involving new disease-gene associations or expansion of phenotype discoveries STAMFORD, Conn., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Throughout 2022, GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, contributed a significant amount – 22% – of... Read More

STAMFORD, Conn., Jan. 27, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the pricing of offerings for an aggregate of 428,571,429 shares of its Class A common stock at a public offering price of $0.35 per share (the “Offerings”). The Offerings consist of an underwritten public offering (the “Underwritten Offering”) of 328,571,429 shares and a registered direct offering (the “Direct Offering”) of... Read More

STAMFORD, Conn., Jan. 26, 2023 (GLOBE NEWSWIRE) -- G eneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it intends to commence an underwritten public offering of its Class A common stock. In addition, GeneDx intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its Class A common stock... Read More

Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (Nasdaq: WGS),... Read More

STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland , President and Chief Executive Officer, will deliver a formal presentation on Thursday, January 12, 2023, at 10:30 a.m. PT. A live and archived webcast of the presentation will be available... Read More